Palopegteriparatide

New to peptides? Start with what are peptides? and how do peptides work?

Overview

Palopegteriparatide, marketed as Yorvipath, addresses a gap that had persisted in endocrinology for a long time. Hypoparathyroidism is one of the few hormone-deficiency diseases that was not conventionally treated by replacing the missing hormone. Instead, patients were managed with large doses of calcium and active vitamin D — a workaround that raises blood calcium without restoring normal calcium handling, and that carries a long-term burden on the kidneys.

The design

The obstacle to true replacement was pharmacokinetic. Parathyroid hormone has a very short half-life, and giving it as a simple daily injection produces a sharp spike followed by a long trough. Calcium then swings with it, which is neither comfortable nor physiologically correct. Palopegteriparatide solves this by attaching PTH(1-34) to an inert carrier through a linker that hydrolyzes at a predictable rate. The molecule is inactive as administered; the carrier releases the active hormone slowly and continuously, producing steady PTH exposure across 24 hours from a single daily injection.

Its place among the PTH drugs

Three PTH-based drugs appear in this encyclopedia and they are not interchangeable. Teriparatide and abaloparatide are used for osteoporosis, and they work precisely because they are intermittent — brief daily peaks of PTH signaling favor bone formation. Palopegteriparatide is used for hypoparathyroidism, and it works precisely because it is continuous — steady levels restore normal calcium regulation. Same hormone, opposite pharmacokinetic goals, different diseases.

It was approved by the FDA in August 2024 and is a prescription medicine used under endocrinology supervision.

How it works

What parathyroid hormone does

PTH is the body's principal calcium regulator. It raises blood calcium through three routes: increasing calcium reabsorption in the kidney so less is lost in urine, promoting release of calcium from bone, and stimulating the kidney to convert vitamin D into its active form, which increases calcium absorption from the intestine. It simultaneously promotes phosphate excretion.

What goes wrong in hypoparathyroidism

Most commonly the parathyroid glands are damaged or removed during neck surgery, though autoimmune and genetic causes exist. Without PTH, blood calcium falls and phosphate rises. Patients experience tingling, muscle cramps, spasms, cognitive fog, and fatigue, and in severe cases seizures. Conventional therapy raises calcium with supplements and active vitamin D, but it does not restore the kidney's calcium-conserving function — so a large calcium load passes into the urine, which over years contributes to kidney stones, nephrocalcinosis, and declining kidney function.

How the prodrug works

Palopegteriparatide circulates as an inactive conjugate. The linker cleaves at a rate determined by chemistry rather than by enzymes, releasing free PTH(1-34) steadily. The released hormone acts on the same PTH1 receptor as natural PTH, restoring renal calcium reabsorption and normal phosphate handling. Because exposure is continuous rather than spiking, the goal is normal calcium regulation rather than the bone-building effect sought in osteoporosis.

The practical aim of this design is that patients can stop or greatly reduce conventional calcium and active vitamin D — not merely add another drug on top of them.

Clinical evidence

The PaTHway trial

Approval rested on PaTHway, a randomized, double-blind, placebo-controlled Phase 3 trial in adults with chronic hypoparathyroidism. At 26 weeks, a large majority of participants on palopegteriparatide achieved the composite endpoint of normal blood calcium while being independent of conventional therapy — compared with a very small proportion on placebo. Essentially all treated participants were able to discontinue active vitamin D and reduce calcium supplementation to minimal levels.

Durability and kidney outcomes

Open-label extension data through 52 weeks and beyond reported that calcium control and independence from conventional therapy were maintained rather than fading. Analyses also reported improvements in estimated kidney function and reductions in urinary calcium excretion — outcomes that matter a great deal in a disease where renal damage accumulates silently over decades. Patient-reported symptom and quality-of-life measures also improved, which is relevant given how much of the burden of hypoparathyroidism is symptomatic rather than visible on a blood test.

How to read this evidence

This is regulator-reviewed randomized evidence in the target population, which places it in the highest evidence tier used on this site. Two honest caveats: hypoparathyroidism is a rare disease, so trial populations are modest in size; and the longest-term outcomes that ultimately matter most — kidney preservation over decades — are inferred from surrogate measures rather than proven yet.

Forms & how it's given

Palopegteriparatide is given as a once-daily subcutaneous injection using a prefilled multi-dose pen. Treatment is initiated and titrated by an endocrinologist, with the dose adjusted against blood calcium while conventional calcium and active vitamin D are tapered in parallel.

The titration phase requires frequent laboratory monitoring, because the point of treatment is to move the patient off their previous regimen without letting calcium swing too high or too low in the process. Once stable, monitoring becomes less frequent but does not stop. The pen requires refrigeration and has specific handling instructions.

We do not publish dosing protocols. This is a specialist-managed replacement therapy whose dosing is inseparable from individual laboratory monitoring.

Safety & status

Reported effects

• Injection-site reactions — the most commonly reported effect.
• Changes in blood calcium in either direction. Hypercalcemia can occur, particularly during titration or if conventional therapy is not tapered appropriately; hypocalcemia can occur if the dose is reduced or interrupted. Both are the reason for structured monitoring.
• Headache, nausea, and diarrhea have been reported.
• Class considerations for PTH analogs around potential effects on bone, carried over from the osteosarcoma signal seen historically in rodent studies of PTH drugs. Regulatory positions on this have evolved as long-term human data accumulated, and prescribers weigh it in individual cases.

Practical cautions

Because it is a replacement therapy for a hormone the body cannot make, abrupt interruption risks symptomatic low calcium. Patients are counseled on recognizing symptoms and on what to do if doses are missed or if illness interferes with treatment.

Legal status

Palopegteriparatide is FDA-approved and prescription-only, dispensed through the regulated supply chain, typically with specialty pharmacy involvement. It is a genuine approved peptide medicine for a rare disease, not a research compound, and it has no consumer or performance market of any kind.

The parathyroid hormone drugs compared

All three deliver PTH or a PTH fragment, but they exploit opposite pharmacology. Brief daily pulses of PTH signalling build bone; continuous PTH exposure restores normal calcium handling. Same hormone, opposite goals.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Khan AA, Rubin MR, Schwarz P, et al. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023. Peer-reviewed study
2. Clarke BL, Khan AA, Rubin MR, et al. Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2025. Peer-reviewed study
3. Rejnmark L, Gosmanova EO, Khan AA, et al. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024. Peer-reviewed study
4. Khan S, Khan AA. Hypoparathyroidism: diagnosis, management and emerging therapies. Nat Rev Endocrinol. 2025. Peer-reviewed study